HC Wainwright & Co. Reiterates Neutral on Lyell Immunopharma, Maintains $1 Price Target
Mitchell Kapoor Maintains Hold Rating on Lyell Immunopharma Amid Promising IMPT-314 Results and Market Challenges
Lyell Immunopharma Cut to Underperform From Buy by B of A Securities
Lyell Immunopharma Price Target Maintained With a $1.00/Share by HC Wainwright & Co.
Lyell Immunopharma Analyst Ratings
H.C. Wainwright Downgrades Lyell Immunopharma(LYEL.US) to Hold Rating, Cuts Target Price to $1
Neutral Rating for Lyell Immunopharma Amid Strategic Shifts and Competitive Challenges
Lyell Immunopharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Lyell Immunopharma (LYEL) and Janux Therapeutics Inc (JANX)
B of A Securities Maintains Buy on Lyell Immunopharma, Lowers Price Target to $6
HC Wainwright & Co. Downgrades Lyell Immunopharma to Neutral, Lowers Price Target to $1
Lyell Immunopharma Analyst Ratings
Bank of America Securities Keeps Their Buy Rating on Lyell Immunopharma (LYEL)
Lyell Immunopharma Analyst Ratings
Lyell Immunopharma Analyst Ratings
HC Wainwright & Co. Maintains Buy on Lyell Immunopharma, Lowers Price Target to $8
Lyell Immunopharma Analyst Ratings
Promising Financial and Clinical Prospects: A Comprehensive Buy Rating Analysis for Lyell Immunopharma
JP Morgan Downgrades Lyell Immunopharma to Neutral, Lowers Price Target to $5
Lyell Immunopharma Analyst Ratings
No Data
No Data